



RECEIVED #13  
NOV 21 2002 12/3/02  
TECH CENTER 1600/2900 87  
PATENT

Docket No.: 44033-122

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Marc J. MCKENNON, et al.

Application No.: 09/859,503 ✓

Filed: May 18, 2001 ✓

For: PYRIDOPYRIMIDINE COMPOUNDS AND THEIR USES ✓

Group Art Unit: 1624

Examiner: M. Berch

INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In accordance with 37 C.F.R. 1.56, the attention of the Patent and Trademark Office is directed to the cited reference(s) listed on the attached PTO-1449. No representation is made or intended that more relevant information does not exist or that the order of presentation of the information in any way reflects their relative pertinence. Applicant(s) respectfully request(s) that the cited information be expressly considered during the prosecution of this application and that the cited reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom. If required, a copy of each reference is attached.

☐ 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. Thus, no certification or fee is required.

☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.

☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counter-part foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. 1.97(e)(1).

☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual

designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. 1.97(e)(2).

☐ c. Please charge the amount of \$180.00 in payment of the fee under 37 C.F.R. 1.17(p). Please credit or debit Deposit Account No. 50-0417 as needed to ensure consideration of the disclosed information. A duplicate copy of this paper is attached.

☒ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) petition(s) that the Information Disclosure Statement be considered. Please charge Deposit Account No. 50-0417 in the amount of \$180.00 for payment of the petition fee. Please credit or debit Deposit Account No. 50-0417 as needed to ensure consideration of the disclosed information. A duplicate copy of this paper is attached.

☒ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. 1.97(e)(1).


☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. 1.97(e)(2).

Please grant any extension of time deemed necessary for entry of this communication. Please charge any deficient fees, or credit any overpayment of fees associated with this communication to Deposit Account No. 50-0417.


Respectfully submitted,

Date: November 20, 2002

By:

  
Cameron K. Weiffenbach  
Registration No. 44,488

McDERMOTT, WILL & EMERY  
600 13th Street, N.W.  
Washington, D.C. 20005-3096  
Telephone: (202) 756-8000  
Facsimile: (202) 756-8087

<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>   (PTO-1449)				ATTY. DOCKET NO. <b>44033-0122</b>		SERIAL NO. <b>09/859,503</b>	
				<b>RECEIVED</b> NOV 21 2002			
				APPLICANT <b>Mark J. McKennon, et al.</b>			
				FILING DATE <b>May 18, 2001</b>		GROUP <b>TECH CENTER 1600/2900</b>	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	5,264,437	11/23/93	Wilhelm, Robert S. et al.				
	3,235,554	02/15/66	Papesch, Viktor				
	5,556,854	09/17/96	Furrer, Harald et al.				
	4,880,810	11/14/89	Lowe III, John A.				
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
	0 994 113	04/19/00	EP			Yes	No
	0 696 590	02/14/96	EP				
	0 608 565	08/03/94	EP				
	1 401 549	11/14/89	GB				
<b>OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	Anderson, G.L. et al. "Pyridopyrimidines. 6. Nucleophilic Substitutions in the Pyrido U2, 3-Dpyrimidine Series" Journal of Organic Chemistry, American Chemical Society, Easton, US, vol. 42, no. 6, 1977, pages 993-996.						
EXAMINER				DATE CONSIDERED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.